All the Drug Class Drugs
EGFR Inhibitor, Kinase Inhibitor. Vandetanib 100 mg. FC TABS: 30 x 100mg. Recom.
dose 300mg 1x dly. Pts. must be given
patient alert card and be informed of
risks Assess QTc interval prior to init.
tmt. Can reduce dosage if necess.
Tmt. aggressive and sympt. medullary
thyroid cancer (MTC) in pts. with
unresectable locally advanced or
metastatic dis. Pts.in whom Rearranged
during Transfection (RET) mutation is not
known or is neg., a possible lower benefit
should be taken into account. See lit.
C/I: Hypersens. to active subst. or excip;
congenital long QTc syndrome; pts. with
QTc interval > 480msec.; concomit. use
of arsenic, cisapride,erythromycin, iv.
toremifene, mizolastine moxifloxacin,
class Ia and III antiarrhythmics. See lit.
EGFR Inhibitor, Monoclonal Antibody. Cetuximab 5 mg/ml. VIAL (I.V. infus.): 10 ml, 20 ml, 50 ml, 100
ml. Initial: 400 mg/m2, foll. by 1 x wkly
dose: 250 mg/m2.
Dosage must be individ. adjust.
according to pt. med. cond.
Tmt. of pts. with (EGFR)-expressing, RAS
wild-type metast. colorectal canc. incomb.
with irinotecan-based chemot., in 1st -line
in comb. with FOLFOX, as a single agent
in pts. who have failed oxaliplatinand
irinotecan- based ther. and whoare
intoler. to irinotecan. Tmt. of pts. With
squamous cell canc. of the head and neck
(SCCHN), in comb. with rad. ther.forlocal.
advanced dis., in comb. With platinumbased
chemo. for recur. and/or metast.
dis., as a single agent after fail. of
platinum-based chemo. for recur.and/or
C/I: Severe hypersens, The comb. With
oxaliplatin-cont. chemot. is contraindic.
for pts. with mutant RAS metast.
colorectal canc. (mCRC) or for whom
RAS mCRC status is unknown.
Contraind. for concom. used chemot.
agents or rad. therapy must be
considered before init. of comb. tmt.
EGFR Inhibitor. Gefitinib 250 mg. F.C. TABS: 30. Swall. whole 1 tab dly, with/
out food, as monother. in advanced
non-small-cell lung cancer (NSCLC)
prev. receiv. tmt. with cytotox.
chemother. Not recommend. child/
adolesc. No adjust reqd. in pt. age,
bdy. wt., gender, ethnicity, ren. funct.
Poorly tol. diarrh./skin adverse drug reacts: Brief (up to 14 days) ther.
interrupt foll. by reinstate 250 mg
Tmt. local advanced/metastat. NSCLC
who have prev. received chemother.